Новости
хирургии
Журнал включен
в систему цитирования Scopus



2014 г. №6 Том 22

ОБЗОРЫ

DOI: http://dx.doi.org/10.18484/2305-0047.2014.6.735   |  

Е.А. ШЛЯХТУHОВ

МИHИМАЛЬHАЯ ОСТАТОЧHАЯ БОЛЕЗHЬ ПРИ СОЛИДHЫХ ОПУХОЛЯХ – СОВРЕМЕHHОЕ СОСТОЯHИЕ ПРОБЛЕМЫ

УО «Витебский государственный медицинский университет»,
Республика Беларусь

В статье представлен обзор современной литературы по вопросам диагностики минимальной остаточной болезни (МОБ) при солидных опухолях. Отдаленные метастазы остаются главной причиной смерти пациентов со злокачественными новообразованиями. МОБ определяется как присутствие опухолевых клеток, которые не могут быть обнаружены на основе использования сегодняшних рутинных диагностических методов, применяющихся для определения стадии опухолевого процесса. Установлено, что у 20-45% онкологических пациентов с категорией М0 в периферической крови обнаруживаются циркулирующие опухолевые клетки (ЦОК), а у 25–60% пациентов диссеминированные опухолевые клетки (ДОК) обнаруживаются в костном мозге. В настоящее время ЦОК и ДОК предложено отнести к категории МОБ. Установлен порог количества ЦОК, который составляет 5 ЦОК в 7,5 мл крови. Наличие ≥5 опухолевых клеток в 7,5 мл периферической крови ассоциируется с плохим прогнозом. В настоящее время для поиска ЦОК применяется один коммерчески доступный прибор одобренный FDA – CellSearch (Veridex LLC) для мониторинга лечения пациенток, страдающих раком молочной железы, колоректальным раком и раком предстательной железы. Кроме того, используя различные модификации ПЦР-анализа, возможна идентификация опухоль-ассоциированных генов, таких как ген тирозиназы (TYR), ген сурвивина (BIRC5), ген рецептора эпидермального фактора роста (ErbB-2/HER2-Neu), а также генов «домашнего хозяйства» (GAPDH, 18S rRNA). Данные гены рассматриваются в настоящее время также, как маркеры МОБ.

Ключевые слова: минимальная остаточная болезнь, метастазирование, солидная опухоль, диагностика
с. 735-742 оригинального издания
Список литературы
  1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006 Nov 17;127(4):679–95.
  2. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;(14):146–47.
  3. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol [Electronic resource]. 2010. Available from: http://www.hindawi.com/journals/jo/2010/617421.
  4. Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 2011 Apr 21;9:43.
  5. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011 Jun 15;17(12):3903–12.
  6. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S.Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009 Nov 15;15(22):6980–86.
  7. Negin BP, Cohen SJ.Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol. 2010 Jun;11(1-2):1–13.
  8. Fidler IJ.The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003 Jun;3(6):453–58.
  9. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002 Jul;8(7):2073–84.
  10. Hayes DF, Smerage J.Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res. 2008 Jun 15;14(12):3646–50.
  11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF.Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781–91.
  12. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K.Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007 Feb 1;13(3):920–28.
  13. Pachmann K, Camara O, Kavallaris A, Schneider U, Schunemann S, Hoffken K.Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res. 2005;7(6):R975–79.
  14. Pantel K, Alix-Panabieres C, Riethdorf S.Cancer micrometastases. Nat Rev Clin Oncol. 2009 Jun;6(6):339–51.
  15. Ghossein RA, Bhattacharya S, Rosai J.Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999 Aug;5(8):1950–60.
  16. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009 Apr 1;69(7):2912–18.
  17. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007 Aug 18;253(2):180–204.
  18. Harach HR, Franssila KO, Wasenius VM.Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 1985 Aug 1;56(3):531–38.
  19. Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa P. Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screening. J Clin Oncol. 2004 Jan 1;22(1):102–7.
  20. Camara O, Kavallaris A, Noschel H, Rengsberger M, Jorke C, Pachmann K.Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol. 2006 Sep 26;4:67.
  21. Pantel K, Alix-Panabieres C, Riethdorf S.Cancer micrometastases. Nat Rev Clin Oncol. 2009 Jun;6(6):339–51.
  22. Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199–15.
  23. Xiao D, Zeng Y, Singh SV.Diallyl trisulfide-induced apoptosis in human cancer cells is linked to checkpoint kinase 1-mediated mitotic arrest. 2009 Nov;48(11):1018–29.
  24. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737–40.
  25. Суконко ОГ, Красный СА. Алгоритмы диагностики и лечения злокачественных новообразований. Минск, РБ. 2012;(вып 2). 508 с.
  26. Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA. Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer. 2007 Dec;43(18):2645–50.
  27. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G.Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000 Feb 24;342(8):525–33.
  28. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr;American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287–12.
  29. Janni W. Circulating tumor cells as predictors of recurrence in primary breast cancer. Germany Breast Cancer Research 2007;9(Suppl 1):S2.
  30. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Jul 1;26(19):3213–21.
  31. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb;7(6):471–79.
  32. Pachmann K, Camara O, Kroll T, Gajda M, Gellner AK, Wotschadlo J, Runnebaum IB.Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol. 2011 Sep;137(9):1317-27.
  33. De Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 2007 Jun 15;13(12):3611–16.
  34. Clarke MF1, Fuller M.Stem cells and cancer: two faces of eve. Cell. 2006 Mar 24;124(6):1111–15.
  35. Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, Alran S, Giacchetti S, Marty M, Lebofsky R, Pierga JY.Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. Int J Breast Cancer. 2013;2013:130470.
  36. Aguirre-Ghiso JA.Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007 Nov;7(11):834–46.
  37. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393–98.
  38. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW.Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol. 2002 Nov;21(5):1111–17.
  39. Laboratory Information System (LIS) Guide - CellSearch [Electronic Resource]. Available from: http://www.cellsearchctc.com.
  40. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20;450(7173):1235–39.
  41. Hoshino K, Huang YY, Lane N, Huebschman M, Uhr JW, Frenkel EP, Zhang X. Microchip-based immunomagnetic detection of circulating tumor cells. Lab Chip. 2011 Oct 21;11(20):3449–57.
  42. Wang H, Chen NG, Minev BR, Zimmermann M, Aguilar RJ, Zhang Q, Sturm JB, Fend F, Yu YA, Cappello J, Lauer UM, Szalay AA Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains. PLoS One. 2013 Sep 3;8(9):e71105.
  43. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr. 2007 Aug;1162:154–61.
  44. Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011 Feb;31(2):427–41.
  45. Swennenhuis JF, Tibbe AG, Levink R, Sipkema RC, Terstapp en LW. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A. 2009 Jun;75(6):520–27.
  46. Tibbe AG, Miller MC, Terstappen LW.Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 2007 Mar;71(3):154–62.
  47. Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, Ionescu-Zanetti C. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qpcr assay. Transl Oncol. 2013 Oct 1;6(5):528–38. eCollection 2013.
  48. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002 Jun 18;3(7):RESEARCH0034.
Адрес для корреспонденции:
210023, Республика Беларусь,
г. Витебск, пр. Фрунзе, д. 27,
УО «Витебский государственный
медицинский университет»,
кафедра онкологии с курсами ЛД, ЛТ, ФПК и ПК,
тел. раб.:+375 212 57-64-16,
e-mail: Evgenij-shlyakhtunov@yandex.ru,
Шляхтунов Евгений Александрович
Cведения об авторах:
Шляхтунов Е.А., к.м.н., доцент кафедры онкологии с курсами ЛД, ЛТ, ФПК и ПК УО «Витебский государственный медицинский университет».
Контакты | ©Витебский государственный медицинский университет, 2007